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Introduction. Brachytherapy as a boost in breast cancer, after conservative surgery and whole breast external beam radiotherapy
is a well known and accepted type of treatment. Traditionally in breast brachytherapy the dose used to be prescribed over the
basal points, following the paris system in a theoretical dosimetry. Nowadays, 3D planiﬁcation systems have been incorporated,
so the PTV can be delineated on the CT-scan . Dosimetric and dose distribution differences can be found between the two types
of planiﬁcation.
Purpose. To evaluate the different dose distributions between the prescription over the basal points and the prescription over the
PTV points.
Materials and methods. We analyze 6 patients 3D brachytherapy dosimetries, and in every case we compare the dose, prescribing
over the basal points and prescribing over the PTV points, determining in every type of planiﬁcation the V150, V200 and D90.
Results. When the dose is prescribed over the PTV points, D90 is higher tan when the dose is prescribed over the basal points in
every patient. V150 and V200 are also higher when the dose is prescribed over the PTV points, but in any case the V200 exceeds
10 cm3, and any case V150 exceeds 15 cm3.
Conclusions. When a 3D CT-scan planiﬁcation is done, prescribing over the PTV obtains a better covering of the target and does
not exceed the limits of the high dose RTOG recommendations.
http://dx.doi.org/10.1016/j.rpor.2013.03.020
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Patients and method. A male 58 year old patient, with a history of primary carcinoma of the trachea T2N1M0 large cell, treated with
chemotherapy and radical radiotherapy in 2007 and intratracheal stent of Poliﬂex. In 2009, was made a periprosthetic accurate
resection of granulomas in the proximal and distal area and mitomycin C locally application. In June 2011 it was operated
to partial breakage of the prosthesis, it not being removable. In the June 2012, objective excrescencies mucosal lesions in the
bronchial tree left in separation carina LSI with LII, suggestive of carcinoma in situ it was seen on ﬁbrobronchoscopy. Pathology
microinvasive squamous carcinoma, with areas of carcinoma in situ. It was made an extension’s study and it was classify as
T1N0M0. Given the characteristics of the patient and tracheal tumor prior radiotherapy and salvage surgery impossible, primary
radical brachytherapy treatment was decided.
Results. It has been calculated the doses received for the treatment of the tracheal tumor, that has been of 1230 cGy, in the
zone currently affects It has been programmed 4 or 5 sessions of endobronchial brachytherapy with high rate of doses with the
team VarisourceTM unit and punctual source of 0.5 cm of I-131, around the affected areas, making the collocation of the plastic
endobronchial catheter of VARIAN of 4.7 Fr and 150 cm, simulation TAC in situ and dosimetric calculation with application of the
session right after, previous displacement of the patient from the TAC’s room, with mobile table, to the brachytherapy’s bunker.
It was applied initially 4 sessions of 5Gy with calculation at 10mm from the central axis of the radioactive source and 5 cm
active length. The lesion measured approximately 2.5 cm and it was left one centimeter of margin inside the axial axis. In the 4◦
session it was objectiﬁed a macroscopic disappearance of the lesion and it was given a 5◦ session of consolidation, receiving in
total 25Gy with interval between sessions from 1 to 2 weeks. In the 5◦ session it was taken a biopsy of the erythematosis area
and it was conﬁrm in anatomapatological inform the absence of illness.
Conclusion. The primary radical brachytherapy is a feasible treatment and that can be offered in patients without no other
alternatives and incipient lesions.
http://dx.doi.org/10.1016/j.rpor.2013.03.021
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Objective. Intermediate risk patients of prostate cancer are a heterogeneous subgroup, since the probability to develop extrapro-
static disease is variable. The treatment of choice is the combination of conformal radiotherapy (CRT) +Brachytherapy but there
are some patients who may beneﬁt from exclusive brachytherapy.
